Review



cb-5339  (Alturas Analytics Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Alturas Analytics Inc cb-5339
    Clinical trial schema for the comparative study of <t>CB-5339</t> in tumor-bearing pet dogs. 2-week (Panel A) and 3-week dosing schedules (Panel B) were utilized in this clinical trial. PE = physical examination; BMA = bone marrow aspiration cytology; PBMCs = peripheral blood mononuclear cells; CBC = complete blood count; chem = serum biochemical panel; UA = urinalysis; PK = pharmacokinetic assessment; PO = per os/oral dosing.
    Cb 5339, supplied by Alturas Analytics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cb-5339/pmc09538592-271-13-6?v=Alturas+Analytics+Inc
    Average 90 stars, based on 1 article reviews
    cb-5339 - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "Comparative oncology assessment of a novel inhibitor of valosin-containing protein in tumor-bearing dogs"

    Article Title: Comparative oncology assessment of a novel inhibitor of valosin-containing protein in tumor-bearing dogs

    Journal: Molecular cancer therapeutics

    doi: 10.1158/1535-7163.MCT-22-0167

    Clinical trial schema for the comparative study of CB-5339 in tumor-bearing pet dogs. 2-week (Panel A) and 3-week dosing schedules (Panel B) were utilized in this clinical trial. PE = physical examination; BMA = bone marrow aspiration cytology; PBMCs = peripheral blood mononuclear cells; CBC = complete blood count; chem = serum biochemical panel; UA = urinalysis; PK = pharmacokinetic assessment; PO = per os/oral dosing.
    Figure Legend Snippet: Clinical trial schema for the comparative study of CB-5339 in tumor-bearing pet dogs. 2-week (Panel A) and 3-week dosing schedules (Panel B) were utilized in this clinical trial. PE = physical examination; BMA = bone marrow aspiration cytology; PBMCs = peripheral blood mononuclear cells; CBC = complete blood count; chem = serum biochemical panel; UA = urinalysis; PK = pharmacokinetic assessment; PO = per os/oral dosing.

    Techniques Used:

    Comparisons of pharmacokinetic exposures obtained from n = 12 canine cancer patients receiving the Powder in Capsule formulation of CB-5339.
    Figure Legend Snippet: Comparisons of pharmacokinetic exposures obtained from n = 12 canine cancer patients receiving the Powder in Capsule formulation of CB-5339.

    Techniques Used: Formulation

    Comparisons of pharmacokinetic exposures obtained from n = 12 canine cancer patients receiving the human clinical formulation of CB-5339.
    Figure Legend Snippet: Comparisons of pharmacokinetic exposures obtained from n = 12 canine cancer patients receiving the human clinical formulation of CB-5339.

    Techniques Used: Formulation

    Comparison of timecourse samples representative of induction of pharmacodynamic markers K48 linkage-specific ubiquitin (A) and CHOP (B, by mRNA) in serial biopsy samples taken from 6 dogs receiving the human clinical formulation of CB-5339.
    Figure Legend Snippet: Comparison of timecourse samples representative of induction of pharmacodynamic markers K48 linkage-specific ubiquitin (A) and CHOP (B, by mRNA) in serial biopsy samples taken from 6 dogs receiving the human clinical formulation of CB-5339.

    Techniques Used: Comparison, Formulation



    Similar Products

    cb 5339  (MedChemExpress)
    94
    MedChemExpress cb 5339
    Cb 5339, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cb-5339/pm40991439-226-20-22?v=MedChemExpress
    Average 94 stars, based on 1 article reviews
    cb 5339 - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    length derlin  (MedChemExpress)
    94
    MedChemExpress length derlin
    Length Derlin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cb-5339/pm37831771-217-5-41?v=MedChemExpress
    Average 94 stars, based on 1 article reviews
    length derlin - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    cb-5339  (Alturas Analytics Inc)
    90
    Alturas Analytics Inc cb-5339
    Clinical trial schema for the comparative study of <t>CB-5339</t> in tumor-bearing pet dogs. 2-week (Panel A) and 3-week dosing schedules (Panel B) were utilized in this clinical trial. PE = physical examination; BMA = bone marrow aspiration cytology; PBMCs = peripheral blood mononuclear cells; CBC = complete blood count; chem = serum biochemical panel; UA = urinalysis; PK = pharmacokinetic assessment; PO = per os/oral dosing.
    Cb 5339, supplied by Alturas Analytics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cb-5339/pmc09538592-271-13-6?v=Alturas+Analytics+Inc
    Average 90 stars, based on 1 article reviews
    cb-5339 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Clinical trial schema for the comparative study of CB-5339 in tumor-bearing pet dogs. 2-week (Panel A) and 3-week dosing schedules (Panel B) were utilized in this clinical trial. PE = physical examination; BMA = bone marrow aspiration cytology; PBMCs = peripheral blood mononuclear cells; CBC = complete blood count; chem = serum biochemical panel; UA = urinalysis; PK = pharmacokinetic assessment; PO = per os/oral dosing.

    Journal: Molecular cancer therapeutics

    Article Title: Comparative oncology assessment of a novel inhibitor of valosin-containing protein in tumor-bearing dogs

    doi: 10.1158/1535-7163.MCT-22-0167

    Figure Lengend Snippet: Clinical trial schema for the comparative study of CB-5339 in tumor-bearing pet dogs. 2-week (Panel A) and 3-week dosing schedules (Panel B) were utilized in this clinical trial. PE = physical examination; BMA = bone marrow aspiration cytology; PBMCs = peripheral blood mononuclear cells; CBC = complete blood count; chem = serum biochemical panel; UA = urinalysis; PK = pharmacokinetic assessment; PO = per os/oral dosing.

    Article Snippet: An HPLC/MS/MS method was developed at Alturas Analytics, Inc. to determine concentrations of CB-5339 in dog K 2 EDTA plasma in accordance with internal Standardized Operating Procedures.

    Techniques:

    Comparisons of pharmacokinetic exposures obtained from n = 12 canine cancer patients receiving the Powder in Capsule formulation of CB-5339.

    Journal: Molecular cancer therapeutics

    Article Title: Comparative oncology assessment of a novel inhibitor of valosin-containing protein in tumor-bearing dogs

    doi: 10.1158/1535-7163.MCT-22-0167

    Figure Lengend Snippet: Comparisons of pharmacokinetic exposures obtained from n = 12 canine cancer patients receiving the Powder in Capsule formulation of CB-5339.

    Article Snippet: An HPLC/MS/MS method was developed at Alturas Analytics, Inc. to determine concentrations of CB-5339 in dog K 2 EDTA plasma in accordance with internal Standardized Operating Procedures.

    Techniques: Formulation

    Comparisons of pharmacokinetic exposures obtained from n = 12 canine cancer patients receiving the human clinical formulation of CB-5339.

    Journal: Molecular cancer therapeutics

    Article Title: Comparative oncology assessment of a novel inhibitor of valosin-containing protein in tumor-bearing dogs

    doi: 10.1158/1535-7163.MCT-22-0167

    Figure Lengend Snippet: Comparisons of pharmacokinetic exposures obtained from n = 12 canine cancer patients receiving the human clinical formulation of CB-5339.

    Article Snippet: An HPLC/MS/MS method was developed at Alturas Analytics, Inc. to determine concentrations of CB-5339 in dog K 2 EDTA plasma in accordance with internal Standardized Operating Procedures.

    Techniques: Formulation

    Comparison of timecourse samples representative of induction of pharmacodynamic markers K48 linkage-specific ubiquitin (A) and CHOP (B, by mRNA) in serial biopsy samples taken from 6 dogs receiving the human clinical formulation of CB-5339.

    Journal: Molecular cancer therapeutics

    Article Title: Comparative oncology assessment of a novel inhibitor of valosin-containing protein in tumor-bearing dogs

    doi: 10.1158/1535-7163.MCT-22-0167

    Figure Lengend Snippet: Comparison of timecourse samples representative of induction of pharmacodynamic markers K48 linkage-specific ubiquitin (A) and CHOP (B, by mRNA) in serial biopsy samples taken from 6 dogs receiving the human clinical formulation of CB-5339.

    Article Snippet: An HPLC/MS/MS method was developed at Alturas Analytics, Inc. to determine concentrations of CB-5339 in dog K 2 EDTA plasma in accordance with internal Standardized Operating Procedures.

    Techniques: Comparison, Formulation